Cargando…
Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease
BACKGROUND: Phosphate binders, such as lanthanum carbonate, control elevated serum-phosphate levels in patients with end-stage renal disease (ESRD). Lanthanum carbonate is available in oral powder and tablet form. The aim of this survey was to investigate satisfaction with, preference for, and adher...
Autores principales: | Keith, Michael, de Sequera, Patricia, Clair, François, Pedersini, Riccardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Just Medical Media Limited
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081242/ https://www.ncbi.nlm.nih.gov/pubmed/27803726 http://dx.doi.org/10.7573/dic.212300 |
Ejemplares similares
-
Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
por: Persy, Veerle P, et al.
Publicado: (2009) -
Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation – safety, efficacy, and patient adherence
por: Lloret, MªJesús, et al.
Publicado: (2013) -
Encephalopathy caused by lanthanum carbonate
por: Fraile, Pilar, et al.
Publicado: (2011) -
Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
por: Cernaro, Valeria, et al.
Publicado: (2020) -
Pharmacology of the Phosphate Binder, Lanthanum Carbonate
por: Damment, Stephen JP
Publicado: (2011)